Back to results
US 2014/0274791 A1Published application
miRNA BIOMARKERS OF LUNG DISEASE
AssigneeAsuragen, Inc.
InventorsElizabeth Mambo, David Brown, Alex T. Adai, Tiffany Sanford, Stephanie Volz, Ashish Choudhary
Life of this patent
Estimating the term…
Abstract
This application describes miRNAs that may be used as serum or plasma biomarkers for characterizing lung disease in a patient. These miRNA biomarkers may be used alone or in combination with other markers for the diagnosis, prognosis, or monitoring of diseases such as lung cancer.
Claims20
1-19. (canceled)
A method of characterizing a lung disease in a patient as cancerous or benign, comprising the steps of:
- a. reverse transcribing a miRNA in a serum sample;
- b. amplifying the miRNA;
- c. measuring the level of the miRNA;
- d. detecting whether the level of the miRNA is elevated or reduced,
- thereby characterizing the lung disease as cancerous if the miRNA is elevated or reduced,
- wherein the miRNA is chosen from miR-210, miR-155, miR-142-5p, miR-181d, miR-27b, miR-15b, miR-126, miR-21, miR-205, let-7b, let-7c, let-7d, let-7e, let-7f, let-7g, let-7i, miR-10a, miR-100b, miR-130b, miR-132, miR-133b, miR-139, miR-143, miR-152, miR-17-5p, miR-193, miR-194, miR-195, miR-196b, miR-199a*, miR-19b, miR-202, miR-204, miR-206, miR-20b, miR-214, miR-221, miR-27a, miR-296, miR-29a, miR-301, miR-324-3p, miR-324-5p, miR-339, miR-346, miR-365, miR-378, miR-422a, miR-432, miR-485-3p, miR-496, miR-497, miR-505, miR-518b, miR-525, miR-566, miR-605, miR-638, miR-660, miR-93, miR-101, miR-106a, miR-106b, miR-125a, miR-140, miR-145, miR-146a, miR-146b, miR-150, miR-151, miR-15a, miR-181a, miR-181b, miR-185, miR-186, miR-190, miR-191, miR-222, miR-23a, miR-24, miR-26a, miR-26b, miR-30a-5p, miR-30b, miR-30c, miR-30d, miR-30e-5p, miR-320, miR-335, miR-340, miR-342, miR-345, and miR-375.
3 more elements
A method of characterizing a lung disease in a patient, comprising the steps of:
- a. reverse transcribing a first miRNA and a second miRNA in a serum sample;
- b. amplifying the first miRNA and the second miRNA;
- c. measuring the levels of the first miRNA and the second miRNA;
- d. detecting whether the levels of the first miRNA and the second miRNA are elevated or reduced,
- thereby characterizing the lung disease in the patient,
- wherein the first and second miRNA are chosen from miR-210, miR-155, miR-142-5p, miR-181d, miR-27b, miR-15b, miR-126, miR-21, miR-205, let-7a, let-7b, let-7d, let-7f, let-7g, let-7i, miR-101, miR-106a, miR-106b, miR-125a, miR-126*, miR-130b, miR-132, miR-133b, miR-140, miR-145, miR-146a, miR-146b, miR-148b, miR-150, miR-151, miR-15a, miR-181a, miR-181b, miR-185, miR-186, miR-190, miR-191, miR-193a, miR-199a*, miR-202, miR-214, miR-222, miR-23a, miR-24, miR-26a, miR-26b, miR-27a, miR-29b, miR-301, miR-30a-5p, miR-30b, miR-30c, miR-30d, miR-30e-5p, miR-320, miR-324-3p, miR-326, miR-335, miR-340, miR-342, miR-345, miR-346, miR-34a, miR-374, miR-375, miR-378, miR-422a, miR-422b, miR-425, miR-486, miR-496, miR-518b, miR-660, miR-7, miR-92, miR-93, miR-98, miR-99a, and miR-99b.
3 more elements
Dependencies are inferred from the claim text.